Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | CD69 | Q07108 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 3/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 7/20 | 0.31 |
| ▸ | CA2 | P00918 | 7/20 | 0.31 |
| ▸ | CA9 | Q16790 | 7/20 | 0.31 |
| ▸ | CA12 | O43570 | 6/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA6 | P23280 | 2/20 | 0.31 |
| ▸ | CA5A | P35218 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 2/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26554384 | 0.85 | MEN1 (0.41) | LMNACA1CA2CA9PTPN1 | |
| SCHEMBL14928980 | 0.78 | SLC28A1 (0.50) | TDP1 | |
| SCHEMBL16805354 | 0.78 | SLC28A1 (0.50) | TDP1 | |
| SCHEMBL26554402 | 0.78 | SLC28A1 (0.33) | LMNATHRBMAPT | |
| SCHEMBL26554377 | 0.78 | SLC28A1 (0.33) | LMNATHRBMAPT | |
| SCHEMBL26554374 | 0.76 | — | — | |
| SCHEMBL14929229 | 0.76 | P2RY14 (0.46) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL16805325 | 0.76 | P2RY14 (0.46) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL14428109 | 0.76 | MAPT (0.40) | LMNATHRBMAPT | |
| SCHEMBL26554401 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | LMNA 737/4885THRB 659/4885SMN1; SMN2 2116/4885 |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | LMNA 737/4885THRB 659/4885SMN1; SMN2 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.